Ibio vs Lisata Therapeutics
Lisata Therapeutics is the larger business, with $170,000 of revenue in fiscal 2025 against $100,000 for Ibio (1.7 times as much). Ibio grew faster (-75.0% against -83.0%). Lisata Therapeutics kept more of each dollar of sales as profit: a net margin of -9756.5% against -33044.0%. Ibio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | IbioIBIO, 2026 | Lisata TherapeuticsLSTA, 2025 |
|---|---|---|
| Revenue | $100,000 | $170,000 |
| Revenue growth | -75.0% | -83.0% |
| Net income | −$33.0m | −$16.6m |
| Operating margin | -35141.0% | -10711.2% |
| Net margin | -33044.0% | -9756.5% |
| Return on equity | -65.7% | -74.7% |
| Free cash flow | −$23.8m | −$16.0m |
| Cash | $56.4m | $16.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 21 |
| Market value | $45.5m | $9.8m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 5 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 0 buys, 0 sales |